July 2011 Volume 7, Issue 7

Volume 7, Issue 7 | July 2011

July 2011

In this Issue

Global News

Drug Discovery News Placeholder Image

Shire PLC acquires Advanced BioHealing for $750M

Creation of new strategic platform based on tissue regeneration using cell-based therapies complements Shire\'s existing specialist physician focus and biologics manufacturing capability
Drug Discovery News Placeholder Image

A Valeant recovery

Valeant Pharmaceuticals signs $446 million deal to acquire Lithuanian company Sanitas shortly after failed bid to take over Cephalon
Drug Discovery News Placeholder Image

Takeda takes on transformation

Japanese pharma acquires European footprint with $13.7 billion purchase of Switzerland-based Nycomed
Drug Discovery News Placeholder Image

Teva spins the globe again

In effort to reduce reliance on U.S. markets, Teva cuts another global deal
Drug Discovery News Placeholder Image

BioCis Pharma and Lx Therapies merge

New specialty pharmaceutical company will target inflammatory diseases and cancers

Diagnostics

Drug Discovery News Placeholder Image

Going for growth

Thermo Fisher's $3.5 billion acquisition of Phadia should position it well in high-growth, high-margin specialty diagnostics market
Drug Discovery News Placeholder Image

When chocolate’s not enough

Nestlé’s new Health Sciences arm ventures into specialty pharma with purchase of Prometheus
Drug Discovery News Placeholder Image

Lab21 targets fungal infections

Personalized medicine company acquires molecular diagnostics firm Myconostica
Drug Discovery News Placeholder Image

The power of three

Agendia announces colorectal cancer collaboration with AstraZeneca and the Netherlands Cancer Institute
Drug Discovery News Placeholder Image

Proteostasis, Elan in neurodegenerative disease deal

Partnership combines Proteostasis Network platform with Elan\'s biology, genetics and neurology disease expertise
Drug Discovery News Placeholder Image

IVAX’s first quarter one of mixed results

IVAX Diagnostics Inc. reported net revenues of $4.1 million in the first quarter of 2011, down from $4.65 million last year.
Drug Discovery News Placeholder Image

Congress has questions for J&J, FDA

Lawmaker says FDA lacks sufficient oversight of the pharma’s Puerto Rican plants

Research & Development

Drug Discovery News Placeholder Image

Specifar a special catch for Watson

Acquisition brings significant European commercial presence
Drug Discovery News Placeholder Image

Merck, Roche tackle the A’s and B’s of hepatitis C

Strategic agreement to focus on improving awareness, treatments of disease
Drug Discovery News Placeholder Image

Filling the gap

Evotec partners with PsychoGenics Inc. to provide integrated CNS drug discovery solutions
Drug Discovery News Placeholder Image

Au naturel

Mississippi researchers form partnership to find natural cancer-fighting drugs

Government Watch

Drug Discovery News Placeholder Image

When it pays to tattle

SEC clarifies rules, compensates whistleblowers
Drug Discovery News Placeholder Image

Pay-for-delay in play

FTC files brief in Third Circuit urging reversal of pay-for-delay ruling in lower court
Drug Discovery News Placeholder Image

Biotech industry waits for shot in the arm

California, Pennsylvania reps co- sponsor renewal bill for Qualifying Therapeutic Discovery Project
Drug Discovery News Placeholder Image

Congress proposes big cuts to FDA budget

In an attempt to address what they call America’s “destructive spending pattern,” members of the U.S. House Appropriations Committee have proposed a $285 million cut to the U.S. Food and Drug Administration’s (FDA) 2012 spending bill.
Drug Discovery News Placeholder Image

Congress has questions for J&J, FDA

Lawmaker says FDA lacks sufficient oversight of the pharma’s Puerto Rican plants

Commentary

Drug Discovery News Placeholder Image

Guest Commentary: Developing new treatments for antibiotic-resistant bacteria

There is strong demand for new anti-infectives, but major factors are slowing down their commercialization. There are, however, a variety of promising initiatives, including advances involving non-antibiotic anti-infectives and host defense proteins.

Editor's Focus

Drug Discovery News Placeholder Image

Stem cell research: Sorting fact from fiction

For the stem cell research arena, the main source of public confusion and debate centers on the use of cell lines derived from human embryos. While society has yet to reach consensus on the ethical and moral dilemmas presented by hESC research, it’s important to remember that it’s not the only form of stem cell research.

Special Reports

Drug Discovery News Placeholder Image

The promise, the pitfalls and a paradigm shift, PART 1

The complex history of stem cell research yields hope for improved human health, unresolved concerns
Drug Discovery News Placeholder Image

The promise, the pitfalls and a paradigm shift, PART 2

The complex history of stem cell research yields hope for improved human health, unresolved concerns
Drug Discovery News Placeholder Image

Parts of the whole

Just like stem cells, global research efforts with them are many and varied

Instruments & Informatics

Drug Discovery News Placeholder Image

Showtime at the APOLLO

LabCorp agrees to acquire Clearstone Central Laboratories
Drug Discovery News Placeholder Image

Knowledge is power

With acquisition of Labtronics, PerkinElmer fortifies knowledge-based, enterprise level solutions in core markets
Drug Discovery News Placeholder Image

From enterprise ELN to ‘paper on glass’

Acquisition of Contur Software expands Accelrys’ portfolio with cost-effective, rapid-deployment electronic lab notebook
Drug Discovery News Placeholder Image

Under great strain

OpGen partners with U of Maryland to develop a microbial sequence database

Omics & Systems Biology

Drug Discovery News Placeholder Image

Where no pharma has gone before

AstraZeneca, Heptares hone in on high-value GPCR targets
Drug Discovery News Placeholder Image

Changing the game

SAIC-Frederick, Biomatrica launch partnership focused on improving molecular analysis in cancer research
Drug Discovery News Placeholder Image

Quintiles redux

Quintiles and Population Genetics Technologies join forces as part of the CRO’s new strategy to help biopharma navigate ‘new health’ landscape
Drug Discovery News Placeholder Image

Sequence of events

Complete Genomics to sequence 250 samples for Erasmus University Medical Center for study of cancer and congenital malformations
Drug Discovery News Placeholder Image

Proteomics leaders join forces

Proteomics Innovation Network seeks collaborative solutions to unmet needs in drug discovery, personalized medicine
Subscribe to Newsletter

Subscribe to our eNewsletters

Stay connected with all of the latest from Drug Discovery News.

Subscribe

Sponsored

Gold circles with attached purple corkscrew shapes represent gold nanoparticles against a black background.

Driving gene therapy with nonviral vectors 

Learn why nonviral vectors are on the rise in gene therapy development.
A 3D digital illustration of a viral spike protein on a cell surface, surrounded by colorful, floating antibodies in the background

Milestone: Leapfrogging to quantitative, high throughput protein detection and analysis

Researchers continuously push the boundaries of what’s possible with protein analysis tools.
Blue cancer cells attached to a cellular surface against a bright blue background in a 3D rendering of a cancer infection.

Advancing immuno-oncology research with cellular assays

Explore critical insights into immunogenicity and immunotoxicity assays for cancer therapies.
Drug Discovery News November 2024 Issue
Latest IssueVolume 20 • Issue 6 • November 2024

November 2024

November 2024 Issue

Explore this issue